Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5TIA1
UPID:
MEI1_HUMAN
Alternative names:
Meiosis defective protein 1
Alternative UPACC:
Q5TIA1; B7Z745; Q1XAP1; Q1XAP2; Q8IYJ5; Q8N5K5; Q8N9H3; Q8TC68
Background:
Meiosis inhibitor protein 1, alternatively known as Meiosis defective protein 1, plays a crucial role in the process of meiotic chromosome synapsis. It is implicated in the formation of meiotic double-strand breaks (DSBs) in spermatocytes, a fundamental step for successful meiosis and fertility.
Therapeutic significance:
The protein's mutation is linked to Hydatidiform mole, recurrent, 3, a disorder marked by abnormal pregnancies. Understanding the role of Meiosis inhibitor protein 1 could open doors to potential therapeutic strategies for managing and treating this condition.